Biodesix to Showcase Growth Story at Key Investor Conferences

LOUISVILLE, Colo. – February 24, 2026 – Biodesix, Inc. (Nasdaq: BDSX) today announced its management will engage with the investment community at two high-profile healthcare conferences in March, a move that comes as the diagnostics firm rides a wave of strong financial performance and bullish market sentiment. The company is slated to present at TD Cowen's 46th Annual Health Care Conference in Boston and Barclays 28th Annual Global Healthcare Conference in Miami, providing a critical platform to detail its growth strategy to investors.

Riding a Wave of Record Revenue

Biodesix heads into these crucial meetings on exceptionally strong footing. The company recently released impressive preliminary financial results for the fourth quarter and full-year 2025, significantly outperforming its own raised guidance. Preliminary unaudited revenue for the fourth quarter is estimated at $28.8 million, a staggering 41% increase over the same period in the prior year.

This quarterly performance capped a record-breaking year for the company, with estimated full-year 2025 revenue hitting $88.5 million, a 24% jump from 2024. This figure surpassed the company's previously upwardly revised guidance of $84 to $86 million. Critically, Biodesix also affirmed its guidance of achieving Adjusted EBITDA positivity in the fourth quarter of 2025, a key milestone on its path to sustainable profitability that investors will be watching closely.

The engine behind this growth is the company's Lung Diagnostics division, which is projected to have brought in $25.2 million in the fourth quarter alone. This success is attributed to a combination of higher test volumes, which reached approximately 18,000 for the quarter, an increased average price per test, and improved collection on older claims. This robust commercial execution demonstrates a maturing operational model that is successfully translating its innovative tests into tangible financial results.

Wall Street Signals Strong Confidence

The company's impressive financial trajectory has not gone unnoticed by market analysts, who have adopted a largely positive outlook on its stock. The consensus rating for Biodesix leans heavily toward "Moderate Buy" or "Strong Buy," with some analysts projecting significant upside. Average price targets from various research firms range from $30.00 to over $33.00, suggesting a potential increase of more than 125% from its current trading price.

This optimism is rooted in the company's anticipated growth. Analyst forecasts for 2026 project a revenue growth rate of nearly 38%, a figure that would dramatically outpace the US Diagnostics & Research industry's average. This bullish case is built on Biodesix's plan to continue expanding its commercial footprint, including growing its sales force to approximately 120 representatives by the end of 2026 to further drive adoption of its lung diagnostic tests.

Further bolstering investor confidence is recent insider activity. Over the last quarter, company insiders have purchased significantly more stock than they have sold, a signal often interpreted as a strong belief in the company's future prospects from those who know it best. With insiders owning a substantial 30% of the company, their interests appear closely aligned with those of external shareholders.

Reshaping Lung Cancer Care with Advanced Diagnostics

Beyond the financial metrics, the core of the Biodesix story lies in its clinical impact. The company's flagship diagnostic tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, are at the forefront of the shift toward personalized medicine in oncology. These blood-based tests are designed to help physicians make more informed and timely decisions for patients with lung disease, a critical need in a field where early and accurate diagnosis can dramatically improve outcomes.

The Nodify Lung tests help clinicians assess the risk of malignancy in lung nodules found on CT scans, potentially helping patients avoid unnecessary invasive procedures. The IQLung portfolio provides crucial information to guide treatment decisions for patients diagnosed with lung cancer. This aligns perfectly with major healthcare investment themes for 2026, which emphasize technology-enabled personalized care and non-invasive diagnostic solutions.

Biodesix has been actively validating the clinical and economic utility of its products, with plans to present new data at major scientific meetings. Recent announcements have highlighted presentations at prestigious conferences like the ASCO Annual Meeting and ISPOR, underscoring a commitment to building a robust evidence base for its technology. This focus on data-driven validation is essential for securing broader adoption and reimbursement in a competitive diagnostics landscape dominated by giants like Roche and Abbott.

A Key Partner in Biopharma Innovation

While its patient-facing diagnostic tests are the most visible part of its business, Biodesix's Development Services division is rapidly becoming a significant growth driver and a strategic asset. This segment, which provides scientific and operational capabilities to biopharmaceutical companies and research institutions, saw its revenue grow an explosive 97% year-over-year in the third quarter of 2025.

This B2B arm of the company effectively leverages Biodesix's deep expertise in diagnostic technologies to help partners develop new tests and therapeutics. The company's recently expanded partnership with Bio-Rad Laboratories to develop advanced Droplet Digital™ PCR assays is a prime example of this strategy in action. By acting as an engine for the broader life sciences industry, Biodesix is diversifying its revenue streams and embedding its technology within the future of drug and diagnostic development.

This dual strategy—driving commercial adoption of its own tests while simultaneously enabling innovation for partners—creates a powerful synergistic model. The insights gained from development partnerships can inform its own product pipeline, while its commercial success enhances its credibility as a collaborator. During the upcoming fireside chats, management will likely emphasize how this integrated approach provides a unique competitive advantage and fuels a more resilient growth trajectory. The company's ability to execute on both fronts will be a key point of interest for investors looking at the long-term potential of the firm.